<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937648</url>
  </required_header>
  <id_info>
    <org_study_id>ID-LAS-101</org_study_id>
    <nct_id>NCT03937648</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability With Oral Administration of Ildong COL-144 Tablet in Korean Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double blind, Placebo-controlled, Single-dose, Dose-escalation Study to
      Evaluate Pharmacokinetics, Safety, and Tolerability with Oral Administration of Ildong
      COL-144 tablet in Korean Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax(maximum serum concentration)</measure>
    <time_frame>0hours(predose), 0.17hours, 0.33hours, 0.5hours, 0.67hours, 1hours, 1.5hours, 2hours, 2.5hours, 3hours, 4hours, 6hours, 8hours, 12hours, Day2 0hours(24hours), 30hours, Day3 0hours(48hours), 4day 0hours(72hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast(rea under the curve from the time of dosing to the last measurable concentration)</measure>
    <time_frame>0hours(predose), 0.17hours, 0.33hours, 0.5hours, 0.67hours, 1hours, 1.5hours, 2hours, 2.5hours, 3hours, 4hours, 6hours, 8hours, 12hours, Day2 0hours(24hours), 30hours, Day3 0hours(48hours), 4day 0hours(72hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax(Time to reach maximum plasma concentration)</measure>
    <time_frame>0hours(predose), 0.17hours, 0.33hours, 0.5hours, 0.67hours, 1hours, 1.5hours, 2hours, 2.5hours, 3hours, 4hours, 6hours, 8hours, 12hours, Day2 0hours(24hours), 30hours, Day3 0hours(48hours), 4day 0hours(72hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F(Clearance)</measure>
    <time_frame>0hours(predose), 0.17hours, 0.33hours, 0.5hours, 0.67hours, 1hours, 1.5hours, 2hours, 2.5hours, 3hours, 4hours, 6hours, 8hours, 12hours, Day2 0hours(24hours), 30hours, Day3 0hours(48hours), 4day 0hours(72hours)</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>COL-144 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COL-144 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COL-144 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COL-144 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COL-144 50mg</intervention_name>
    <description>COL-144 50mg</description>
    <arm_group_label>COL-144 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COL-144 100mg</intervention_name>
    <description>COL-144 100mg</description>
    <arm_group_label>COL-144 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COL-144 200mg</intervention_name>
    <description>COL-144 200mg</description>
    <arm_group_label>COL-144 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COL-144 400mg</intervention_name>
    <description>COL-144 400mg</description>
    <arm_group_label>COL-144 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy adult who is at least 19 years old and less than 50 years old at the time of
             the screening visit.

          2. A person whose body mass index (BMI) is greater than 19 kg/m2 and less than 28 kg/m2
             at the time of the screening visit.

          3. A person who is medically confirmed to be clinically insignificant in terms of a
             physical or mental condition by an investigator through a physical examination during
             the screening period.

          4. A person who has agreed to use a combination of effective contraceptive methods or
             medically appropriate contraceptive methods from the date of administration of the
             investigational product to the end of the clinical trial (date of test for final
             safety assessment).

          5. A male or female who has agreed not to provide sperm or eggs.

          6. A woman whose serum/urine human chorionic gonadotropin (hCG) test results were
             negative and who is not pregnant or breastfeeding.

          7. A person who has voluntarily decided and provided written consent to participate in
             clinical trials and follow precautions for test subjects.

          8. A person who can collect blood and urine during the clinical trial, including
             follow-up visits.

        Exclusion Criteria:

          1. A person with a history of gastrointestinal disorders (ex. Crohn's disease, ulcerative
             colitis, etc.) or surgery (except for simple appendectomy or herniotomy) that may
             affect the absorption of the investigational product.

          2. In addition to Exclusion Criteria 1 above, a person with a history of clinically
             significant diseases related to allergy, cardiovascular system, peripheral vascular
             system, skin, mucous membrane, eyes, otolaryngology system, respiratory system,
             musculoskeletal system, infection, gastrointestinal system, liver, biliary system,
             endocrine system, kidney, urogenital system, nervous system, psychiatric system,
             blood, tumor, fracture, and others.

          3. A person with genetically caused galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption.

          4. A person with a history of hypersensitivity or clinically significant hypersensitivity
             to drugs that contain Lasmiditan or ingredients in the same category or other drugs
             (aspirin and non-steroidal anti-inflammatory drugs, antibiotics, etc.).

          5. A person who has a history of drug abuse or whose urine drug screening test result
             during the screening period came back positive for abusive drug use.

          6. A person who has donated partial or full amount of blood within 60 days of the
             screening visit, who has given blood through apheresis within 30 days, or who has been
             transfused within 60 days.

          7. A person who has been administered with the investigational product or a
             bioequivalence study drug in another clinical trial or a bioequivalence study within
             180 days of the screening visit.

          8. A person who has taken a prescription drug, OTC(over the counter drug), herbal
             medicine, or health-functional food within 14 days of the screening visit.

          9. A person who has smoked excessively within 14 days of the screening visit or whose (&gt;
             10 cigarettes/day) urine nicotine test result during the screening period came back
             positive.

         10. A person who drank excessively within 14 days of screening visit (&gt; 21 units/week).

         11. A person who shows the following results in the vitality sign test during the
             screening period.

             Systolic blood pressure ≥ 140 (millimeter of mercury) mmHg or &lt;90 mmHg Diastolic blood
             pressure ≥ 90 mmHg or &lt;60 mmHg Pulse&gt; 100 bpm or &lt; 45 bpm

         12. A person who shows the following in the diagnostic test during the screening period.

               -  Aspartate aminotransferase (AST) and aminotransferase (ALT) values exceed the
                  upper limit of reference (UNL) by more than 1.5 times.

               -  Bilirubin total value exceeds the upper limit of reference (UNL) by more than 1.5
                  times.

         13. A person who tested positive in a blood serum test (hepatitis B test, human
             immunodeficiency virus (HIV) test, hepatitis C test, syphilis test) during the
             screening period.

         14. A person who showed QTc(Heart rate-corrected QT) &gt; 450 ms or clinically significant
             abnormalities in a 12-electrode electrocardiogram during the screening period.

         15. In addition to Exclusion Criteria 12) to 14), a person who was found to be ineligible
             to participate in the clinical trials by the diagnostic test or a 12-electrode
             electrocardiogram.

         16. Any other person who is judged to be inadequate to perform the clinical trials by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

